目的:探讨瑞舒伐他汀对2型糖尿病患者的血脂及血清血管性血友病因子(vWF)、凝血酶调节蛋白(TM)水平的影响。方法:80例2型糖尿病患者随机分为观察组和对照组。两组患者均在饮食调整、适当体育锻炼基础上予以口服降糖药或胰岛素注射治疗。观察组患者加用瑞舒伐他汀片10 mg,po qd,连用12周。比较两组患者治疗前后血脂、血清vWF和TM水平变化及药品不良反应。结果:治疗12周后,观察组总胆固醇(TC)、三酰甘油(TG)和低密度脂蛋白胆固醇(LDL-C)水平均有不同程度下降,高密度脂蛋白胆固醇(HDL-C)水平明显上升(P<0.05);而对照组治疗前后TC、TG、LDL-C和HDL-C水平变化不明显(P>0.05);两组患者血清vWF和TM水平均有不同程度下降(P<0.05或0.01),且观察组下降幅度较对照组更明显(P<0.05)。两组患者治疗中未见明显药品不良反应。结论:瑞舒伐他汀能调节2型糖尿病患者的血脂代谢紊乱,安全性较佳,并能降低患者血清vWF和TM水平,保护和修复血管内皮细胞损伤或调节内皮功能紊乱,在减少与预防心脑血管并发症中起到重要作用。 Objective: To investigate the effect of rosuvastatin on serum lipids and serum vWF and thrombin (TM) levels in type 2 diabetic patients. Methods: Eighty patients with type 2 diabetes were randomly divided into observation group and control group. Two groups of patients in the diet adjustment, appropriate physical exercise on the basis of oral hypoglycemic agents or insulin injection therapy. Observation group patients with rosuvastatin tablets 10 mg, po qd, once every 12 weeks. The changes of serum lipid, serum vWF and TM levels and adverse drug reactions were compared between the two groups before and after treatment. Results: The levels of total cholesterol, triglyceride and low density lipoprotein cholesterol (LDL-C) decreased to some extent in the observation group after 12 weeks of treatment. The level of high-density lipoprotein cholesterol (HDL-C) (P <0.05). However, the levels of TC, TG, LDL-C and HDL-C in the control group did not change significantly before and after treatment (P> 0.05). The serum levels of vWF and TM decreased in both groups (P < 0.05 or 0.01), and the observation group decreased more significantly than the control group (P <0.05). Two groups of patients treated with no obvious adverse drug reactions. Conclusion: Rosuvastatin can regulate blood lipid metabolism in patients with type 2 diabetes, which is safe and can reduce serum vWF and TM levels, protect and repair vascular endothelial cell injury or regulate endothelial dysfunction, reduce the risk of heart failure Cerebrovascular complications play an important role.